-
1
-
-
32644438680
-
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
-
Facon T, Mary JY, Pegourie B, Attal M, Renaud M, Sadoun A, Voillat L, Dorvaux V, Hulin C, Lepeu G, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107: 1292-8.
-
(2006)
Blood
, vol.107
, pp. 1292-1298
-
-
Facon, T.1
Mary, J.Y.2
Pegourie, B.3
Attal, M.4
Renaud, M.5
Sadoun, A.6
Voillat, L.7
Dorvaux, V.8
Hulin, C.9
Lepeu, G.10
-
2
-
-
5644267858
-
Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma
-
Hernandez JM, Garcia-Sanz R, Golvano E, Blade J, Fernandez-Calvo J, Trujillo J, Soler JA, Gardella S, Carbonell F, Mateo G, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004; 127: 159-64.
-
(2004)
Br J Haematol
, vol.127
, pp. 159-164
-
-
Hernandez, J.M.1
Garcia-Sanz, R.2
Golvano, E.3
Blade, J.4
Fernandez-Calvo, J.5
Trujillo, J.6
Soler, J.A.7
Gardella, S.8
Carbonell, F.9
Mateo, G.10
-
3
-
-
0025064260
-
VAD-based regimens as primary treatment for multiple myeloma
-
Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86-9.
-
(1990)
Am J Hematol
, vol.33
, pp. 86-89
-
-
Alexanian, R.1
Barlogie, B.2
Tucker, S.3
-
4
-
-
0032920397
-
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma
-
Segeren CM, Sonneveld P, vanderHolt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: 127-30.
-
(1999)
Br J Haematol
, vol.105
, pp. 127-130
-
-
Segeren, C.M.1
Sonneveld, P.2
vanderHolt, B.3
Baars, J.W.4
Biesma, D.H.5
Cornellissen, J.J.6
Croockewit, A.J.7
Dekker, A.W.8
Fibbe, W.E.9
Löwenberg, B.10
-
5
-
-
0037739753
-
High-dose chemotherapy with hematopoietic stemcell rescue for multiple myeloma
-
Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. High-dose chemotherapy with hematopoietic stemcell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.
-
(2003)
N Engl J Med
, vol.348
, pp. 1875-1883
-
-
Child, J.A.1
Morgan, G.J.2
Davies, F.E.3
Owen, R.G.4
Bell, S.E.5
Hawkins, K.6
Brown, J.7
Drayson, M.T.8
Selby, P.J.9
-
6
-
-
0012689130
-
Impact on survival of highdose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study
-
Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wisloff F, Brinch L, Carlson K, Carlsson M, et al. Impact on survival of highdose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000; 95: 7-11.
-
(2000)
Blood
, vol.95
, pp. 7-11
-
-
Lenhoff, S.1
Hjorth, M.2
Holmberg, E.3
Turesson, I.4
Westin, J.5
Nielsen, J.L.6
Wisloff, F.7
Brinch, L.8
Carlson, K.9
Carlsson, M.10
-
7
-
-
34447121281
-
New drugs for myeloma
-
Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist 2007; 12: 664-89.
-
(2007)
Oncologist
, vol.12
, pp. 664-689
-
-
Richardson, P.G.1
Mitsiades, C.2
Schlossman, R.3
Munshi, N.4
Anderson, K.5
-
8
-
-
48849114364
-
Bortezomib in the front-line treatment of multiple myeloma
-
Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008; 8: 1053-72.
-
(2008)
Expert Rev Anticancer Ther
, vol.8
, pp. 1053-1072
-
-
Richardson, P.G.1
Mitsiades, C.2
Schlossman, R.3
Ghobrial, I.4
Hideshima, T.5
Munshi, N.6
Anderson, K.C.7
-
9
-
-
77950607507
-
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction
-
Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR, Buadi FK, Hogan WJ. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood 2010; 115: 2348-53.
-
(2010)
Blood
, vol.115
, pp. 2348-2353
-
-
Gertz, M.A.1
Kumar, S.2
Lacy, M.Q.3
Dispenzieri, A.4
Dingli, D.5
Hayman, S.R.6
Buadi, F.K.7
Hogan, W.J.8
-
10
-
-
61749103773
-
Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation
-
Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM,Yoon SS, Lee JH. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant 2009; 15: 463-70.
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 463-470
-
-
Kim, J.S.1
Kim, K.2
Cheong, J.W.3
Min, Y.H.4
Suh, C.5
Kim, H.6
Jo, D.Y.7
Ryoo, H.M.8
Yoon, S.S.9
Lee, J.H.10
-
11
-
-
33646339149
-
Complete response in multiple myeloma: clinical trial E9486, an Eastern CooperativeOncology Group study not involving stem cell transplantation
-
Kyle RA, Leong T, Li S, Oken MM, Kay NE, VanNess B, Greipp PR. Complete response in multiple myeloma: clinical trial E9486, an Eastern CooperativeOncology Group study not involving stem cell transplantation. Cancer 2006; 106: 1958-66.
-
(2006)
Cancer
, vol.106
, pp. 1958-1966
-
-
Kyle, R.A.1
Leong, T.2
Li, S.3
Oken, M.M.4
Kay, N.E.5
VanNess, B.6
Greipp, P.R.7
-
12
-
-
33749361262
-
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patientsolder than 65 years with newly diagnosed multiple myeloma
-
Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patientsolder than 65 years with newly diagnosed multiple myeloma. Blood 2006; 108: 2159-64.
-
(2006)
Blood
, vol.108
, pp. 2159-2164
-
-
Offidani, M.1
Corvatta, L.2
Piersantelli, M.N.3
Visani, G.4
Alesiani, F.5
Brunori, M.6
Galieni, P.7
Catarini, M.8
Burattini, M.9
Centurioni, R.10
-
13
-
-
54049135250
-
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
-
Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, Montanaro M, Ria R, Capaldi A, Zambello R, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008; 112: 3107-14.
-
(2008)
Blood
, vol.112
, pp. 3107-3114
-
-
Palumbo, A.1
Bringhen, S.2
Liberati, A.M.3
Caravita, T.4
Falcone, A.5
Callea, V.6
Montanaro, M.7
Ria, R.8
Capaldi, A.9
Zambello, R.10
-
14
-
-
68949137225
-
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
-
Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27: 3664-70.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3664-3670
-
-
Hulin, C.1
Facon, T.2
Rodon, P.3
Pegourie, B.4
Benboubker, L.5
Doyen, C.6
Dib, M.7
Guillerm, G.8
Salles, B.9
Eschard, J.P.10
-
15
-
-
8344251663
-
Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma
-
Ross DM, To LB, Horvath N. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma. Intern Med J 2004; 34: 576-8.
-
(2004)
Intern Med J
, vol.34
, pp. 576-578
-
-
Ross, D.M.1
To, L.B.2
Horvath, N.3
-
16
-
-
77950660221
-
Early response predicts myeloma outcome
-
Palumbo A. Early response predicts myeloma outcome. Blood 2010; 115: 2332-3.
-
(2010)
Blood
, vol.115
, pp. 2332-2333
-
-
Palumbo, A.1
-
17
-
-
2042511646
-
Early response to therapy and survival in multiple myeloma
-
Schaar CG, Kluin-Nelemans JC, le Cessie S, Franck PF, te Marvelde MC, Wijermans PW. Early response to therapy and survival in multiple myeloma. Br J Haematol 2004; 125: 162-6.
-
(2004)
Br J Haematol
, vol.125
, pp. 162-1666
-
-
Schaar, C.G.1
Kluin-Nelemans, J.C.2
Le Cessie, S.3
Franck, P.F.4
Te Marvelde, M.C.5
Wijermans, P.W.6
-
18
-
-
65349142006
-
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
-
Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009; 113: 3435-42.
-
(2009)
Blood
, vol.113
, pp. 3435-3442
-
-
Ludwig, H.1
Hajek, R.2
Tothova, E.3
Drach, J.4
Adam, Z.5
Labar, B.6
Egyed, M.7
Spicka, I.8
Gisslinger, H.9
Greil, R.10
-
19
-
-
34848833957
-
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced- intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
-
Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced- intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209-18.
-
(2007)
Lancet
, vol.370
, pp. 1209-1218
-
-
Facon, T.1
Mary, J.Y.2
Hulin, C.3
Benboubker, L.4
Attal, M.5
Pegourie, B.6
Renaud, M.7
Harousseau, J.L.8
Guillerm, G.9
Chaleteix, C.10
-
20
-
-
50449086728
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
-
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-17.
-
(2008)
N Engl J Med
, vol.359
, pp. 906-917
-
-
San Miguel, J.F.1
Schlag, R.2
Khuageva, N.K.3
Dimopoulos, M.A.4
Shpilberg, O.5
Kropff, M.6
Spicka, I.7
Petrucci, M.T.8
Palumbo, A.9
Samoilova, O.S.10
-
21
-
-
80051548597
-
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression
-
Shah J, Blade J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, Lowery C, Orlowski RZ. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer 2011; 117: 3758-62.
-
(2011)
Cancer
, vol.117
, pp. 3758-3762
-
-
Shah, J.1
Blade, J.2
Sonneveld, P.3
Harousseau, J.L.4
Lantz, K.5
Londhe, A.6
Lowery, C.7
Orlowski, R.Z.8
-
22
-
-
70350094381
-
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
-
Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009; 23: 1716-30.
-
(2009)
Leukemia
, vol.23
, pp. 1716-1730
-
-
Palumbo, A.1
Sezer, O.2
Kyle, R.3
Miguel, J.S.4
Orlowski, R.Z.5
Moreau, P.6
Niesvizky, R.7
Morgan, G.8
Comenzo, R.9
Sonneveld, P.10
-
23
-
-
78149443734
-
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
-
Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010; 116: 3743-50.
-
(2010)
Blood
, vol.116
, pp. 3743-3750
-
-
Harousseau, J.L.1
Palumbo, A.2
Richardson, P.G.3
Schlag, R.4
Dimopoulos, M.A.5
Shpilberg, O.6
Kropff, M.7
Kentos, A.8
Cavo, M.9
Golenkov, A.10
-
24
-
-
35348923502
-
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network
-
Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007; 25: 4459-65.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4459-4465
-
-
Palumbo, A.1
Falco, P.2
Corradini, P.3
Falcone, A.4
Di Raimondo, F.5
Giuliani, N.6
Crippa, C.7
Ciccone, G.8
Omedè, P.9
Ambrosini, M.T.10
-
25
-
-
77955816305
-
Lenalidomide plus dexamethasone vs lenalidomide plus melphalan and prednisone:a retrospective study in newly diagnosed elderly myeloma
-
Gay F, Vincent Rajkumar S, Falco P, Kumar S, Dispenzieri A, Petrucci MT, Gertz MA, Boccadoro M, Keith Stewart A, Palumbo A. Lenalidomide plus dexamethasone vs lenalidomide plus melphalan and prednisone:a retrospective study in newly diagnosed elderly myeloma. Eur J Haematol 2010; 85: 200-8.
-
(2010)
Eur J Haematol
, vol.85
, pp. 200-208
-
-
Gay, F.1
Vincent Rajkumar, S.2
Falco, P.3
Kumar, S.4
Dispenzieri, A.5
Petrucci, M.T.6
Gertz, M.A.7
Boccadoro, M.8
Keith Stewart, A.9
Palumbo, A.10
|